EGFR and non-small cell lung carcinoma: Both osimertinib and almonertinib led to superior progression-free survival (PFS) compared to the first-generation EGFR-TKIs (gefitinib or erlotinib) as first-line treatment in NSCLC patients with EGFR mutations [6, 7].